Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0SZ3B
|
||||
Former ID |
DIB005668
|
||||
Drug Name |
ER-34122
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Terminated | [1], [2] | ||
Company |
Eisai Co Ltd
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C27H26ClN3O5
|
||||
Canonical SMILES |
c1(nn(c(c1)c1ccc(cc1)OC)c1ccc(cc1)OC)C(c1cc(C(=O)N)c(cc<br />1)Cl)(OC)OC
|
||||
CAS Number |
CAS 179325-62-3
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Arachidonate 5-lipoxygenase | Target Info | Modulator | [1], [2] | |
BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
Resolvin D biosynthesis | |||||
Leukotriene biosynthesis | |||||
Lipoxin biosynthesis | |||||
Aspirin triggered resolvin D biosynthesis | |||||
Aspirin triggered resolvin E biosynthesis | |||||
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Toxoplasmosis | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
WikiPathways | Vitamin D Receptor Pathway | ||||
Arachidonic acid metabolism | |||||
Eicosanoid Synthesis | |||||
Selenium Micronutrient Network | |||||
References | |||||
REF 1 | Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66. | ||||
REF 2 | ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm Res. 1998 Oct;47(10):375-83. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.